

HOW A MANUSCRIPT IS PREPARED CAN DETERMINE WHEN IT IS PUBLISHED

FACT:

Seventy-four percent of all non-American manuscripts submitted to American journals are

returned to the author without review and without consideration for publication.

REASON:

Poor English can obscure the results of a successful, meticulous laboratory experiment. According to our recent survey of American editorial offices, manuscripts are delayed, returned unreviewed, or rejected because

imprecise English and improper styling of the manuscript make the science unclear and unreadable. Laboratory advances described in incorrect English can not be reproduced by other laboratories, and therefore are not publishable.

SOLUTION:

BOLDFACE EDITORS, a distinctive editorial service, will provide the expertise to expedite REVIEW, ACCEPTANCE, and PUBLICATION of your work. **BOLDFACE EDITORS** has a staff of senior biomedical editors and

authors with more than 35 years of experience in writing, working in the laboratory, publishing original articles in leading science journals, and evaluating manuscripts for publication.

BOLDFACE EDITORS SERVICES:

BOLDFACE EDITORS will assign a senior editor to your work to ensure the following:

- the manuscript will meet the requirements for submission and can therefore be entered into the review process immediately upon receipt by a journal
- the manuscript will be copyedited and prepared

to enable a journal editor to make a rapid editorial decision on your work

- elimination of unnecessary delay between acceptance and publication resulting from incorrect English
- acceleration of printing of the manuscript in a specific issue of a journal by reducing the number of grammatical changes needed at the proof stage

HOW BOLDFACE EDITORS WORKS:

Upon receipt, your manuscript is immediately assigned to a senior biomedical editor. This editor will perform all the work you have requested. Upon completion, your work is reviewed by at least three additional senior staff editors to ensure

that the service performed conforms to our written standards. **NOTE: Manuscripts accompanied with payment are returned to the author by EXPRESS MAIL, usually within ONE WEEK of receipt.**

WRITE TODAY FOR SERVICES OFFERED:

Incorrect English does delay the publication of valid, successful laboratory advances. Why experiment with poor English? Let your

laboratory achievements speak for themselves—in perfect English—in the NEXT available issue of a leading American journal.

Make **BOLDFACE EDITORS** your FIRST step in the publication of your work.

BOLDFACE EDITORS

A Distinctive Editorial Service

BOLDFACE EDITORS, P.O. Box 707, Planetarium Station, N.Y., N.Y. 10024
Phone: 212 862-6853

**THE NATIONAL NEUROFIBROMATOSIS
FOUNDATION**

announces the availability of

YOUNG INVESTIGATOR AWARDS

which will provide salary support not to exceed \$35,000 annually for periods up to two years, and

RESEARCH GRANTS

which will provide up to \$50,000 for up to two years for research on the cause and treatment of neurofibromatosis

The deadline for filing applications for awards to be activated during the 1989-1990 academic year is April 1, 1989

For information or applications, please contact:

The National Neurofibromatosis Foundation
141 Fifth Avenue, Suite 7-S
New York, NY 10010
212-460-8980
1-800-323-7938 outside New York State
Fax # 212-539-6094

**Help us to
serve you
better.....**



**USE
YOUR
ZIP
CODE**

**Remember, your zip code
provides faster, more direct
delivery of your journals.
Use it on all correspondence,
too.**

**MOVING? RENEWING?
QUESTION? COMPLAINT?**

ATTACH YOUR LABEL HERE All our services to subscribers are faster when you include the subscription label.

Name _____
Address _____
City _____ State _____ Zip _____
Journal Title _____

MOVING? Please give us 8 weeks' notice. Attach your label above when you send us your new address.

WRITE IN NEW ADDRESS

Name _____
Address _____
City _____ State _____ Zip _____

RENEWING? For uninterrupted service, include your label with this coupon.

QUESTION OR COMPLAINT?

Call **free**: 1-800-638-6423; Maryland subscribers call 1-800-638-4007. We can help you most efficiently if the mailing label from your latest issue is in front of you when you call, so that you can provide us with the journal code, volume, issue, and your subscription number. If the problem concerns your payment, please have your canceled check in front of you so that we can solve the problem over the telephone.

- Change of address Payment enclosed
 Renewal Bill me later

Subscription Fulfillment Department
Williams & Wilkins
428 East Preston Street
Baltimore, Maryland 21202




**Progress
in
Cancer
Research**

P-glycoMAb C219™* **and** ***Multi-Drug Resistance to Chemotherapy***

Multiple drug resistance and P170

Data suggest that multiple drug resistance in cancer chemotherapy is associated with elevated levels of P-glycoprotein (P170)¹. P170 is a cell membrane protein that may serve as a pump to actively remove drugs from the cell². Thus, it may be important to further investigate if P170 levels can serve as a possible prognostic indicator of response to chemotherapy.

Research studies have shown elevated P170 levels to be associated with solid tumors and hematologic malignancies such as:




Initial research has begun on the role P170 may play in determining drug resistance to¹:



P-glycoMAb C219™: monoclonal antibody to P170

Centocor's P-glycoMAb C219™ reacts with a P170 epitope expressed inside the cell membrane. Research is being conducted to determine the performance of C219 in detecting P-glycoprotein in:



Now available for research use

To receive a complete scientific fact sheet and bibliography, or to order P-glycoMAb C219™ for research purposes, call 1-800-345-2401 (in Pennsylvania: 215-889-4446).

P-glycoMAb C219 is a trademark of Centocor, Inc.

1. Pastan I, Gottesman M: N Engl J Med 316:1388-1393 (1987).
2. Tsuruo T: Jpn J Cancer Res (Gann) 79:285-296 (1988).
3. Bell DR, et al: J Clin Oncol 3:311-315 (1985).
4. Ma DDF, et al: Lancet 1:135-137 (1987).
5. Fuqua SAW, et al: Cancer Res 47:2103-2106 (1987).
6. Dalton WS, et al: Cancer Res 48:1882-1888 (1988).
7. Procedure on file, Centocor, Inc.
8. Kartner N, et al: Nature 316:820-823 (1985).



CENTOCOR

**Your Connection
to the Future**

244 Great Valley Parkway
Malvern, PA 19355

* FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedure.